Vivos Therapeutics Inc
NASDAQ:VVOS
Balance Sheet
Balance Sheet Decomposition
Vivos Therapeutics Inc
Current Assets | 2.5m |
Cash & Short-Term Investments | 1.6m |
Receivables | 202k |
Other Current Assets | 616k |
Non-Current Assets | 8.3m |
PP&E | 4.7m |
Intangibles | 3.3m |
Other Non-Current Assets | 307k |
Current Liabilities | 7.3m |
Accounts Payable | 2.1m |
Accrued Liabilities | 2.8m |
Other Current Liabilities | 2.3m |
Non-Current Liabilities | 3m |
Other Non-Current Liabilities | 3m |
Balance Sheet
Vivos Therapeutics Inc
Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
---|---|---|---|---|---|---|---|
Assets | |||||||
Cash & Cash Equivalents |
1
|
0
|
18
|
24
|
4
|
2
|
|
Cash Equivalents |
1
|
0
|
18
|
24
|
4
|
2
|
|
Total Receivables |
1
|
1
|
2
|
1
|
0
|
0
|
|
Accounts Receivables |
1
|
1
|
2
|
1
|
0
|
0
|
|
Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Current Assets |
0
|
1
|
1
|
2
|
1
|
1
|
|
Total Current Assets |
2
|
2
|
20
|
27
|
5
|
2
|
|
PP&E Net |
1
|
1
|
1
|
3
|
5
|
5
|
|
PP&E Gross |
1
|
1
|
1
|
3
|
5
|
5
|
|
Accumulated Depreciation |
0
|
1
|
1
|
1
|
2
|
2
|
|
Intangible Assets |
1
|
1
|
0
|
0
|
0
|
0
|
|
Goodwill |
4
|
3
|
3
|
3
|
3
|
3
|
|
Note Receivable |
0
|
1
|
1
|
0
|
0
|
0
|
|
Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Assets |
4
|
3
|
3
|
3
|
3
|
3
|
|
Total Assets |
8
N/A
|
8
-8%
|
25
+235%
|
34
+33%
|
14
-59%
|
11
-22%
|
|
Liabilities | |||||||
Accounts Payable |
0
|
1
|
2
|
1
|
1
|
2
|
|
Accrued Liabilities |
1
|
1
|
2
|
3
|
2
|
3
|
|
Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
|
Current Portion of Long-Term Debt |
0
|
4
|
1
|
1
|
0
|
0
|
|
Other Current Liabilities |
1
|
3
|
3
|
2
|
3
|
2
|
|
Total Current Liabilities |
2
|
9
|
8
|
8
|
7
|
7
|
|
Long-Term Debt |
1
|
0
|
0
|
0
|
0
|
0
|
|
Other Liabilities |
0
|
0
|
0
|
0
|
2
|
3
|
|
Total Liabilities |
3
N/A
|
9
+239%
|
8
-8%
|
8
-3%
|
9
+9%
|
10
+16%
|
|
Equity | |||||||
Common Stock |
1
|
1
|
0
|
0
|
0
|
0
|
|
Retained Earnings |
13
|
23
|
35
|
56
|
79
|
93
|
|
Additional Paid In Capital |
17
|
20
|
52
|
81
|
84
|
93
|
|
Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Equity |
5
N/A
|
2
N/A
|
17
N/A
|
26
+51%
|
5
-81%
|
0
-91%
|
|
Total Liabilities & Equity |
8
N/A
|
8
-8%
|
25
+235%
|
34
+33%
|
14
-59%
|
11
-22%
|
|
Shares Outstanding | |||||||
Common Shares Outstanding |
1
|
1
|
1
|
1
|
1
|
2
|